Hormonal
Second-generation incretin receptor agonists (GLP-1 RAs like semaglutide and liraglutide, and dual GLP-1/GIP agonist tirzepatide) significantly reduce blood pressure and promote weight loss in obesity-related hypertension, outperforming first-generation anti-obesity drugs.
For obesity-related hypertension, second-generation incretin receptor agonists (GLP-1 RAs) like semaglutide (2.4 mg weekly) or liraglutide (3 mg daily) are the most effective pharmacological treatments for lowering blood pressure and promoting weight loss. They significantly outperform older anti-obesity drugs. These medications should be integrated with lifestyle changes (diet and exercise) and are particularly effective in non-diabetic obese patients, though they also benefit those with type 2 diabetes.
second-generation incretin receptor agonists, including the GLP-1 receptor agonists liraglutide and semaglutide, and in particular the dual GLP-1/glucose-dependent insulinotropic polypeptide ( GIP) co-agonist tirzepatide, substantially contribute to effective WL and BP control in obesity.
Why this rating
Supported by multiple RCTs, meta-analyses, and major outcome trials (SELECT, FLOW) cited in the text.
Source
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Aneliya Parvanova et al. · Clinical Kidney Journal · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →